Q&A with Immunomic’s Teri Heiland, PhD: What the ‘UNITE’ Technology Platform Could Mean for the Future of Immunotherapy

Published on :

Q&A with Immunomic’s Teri Heiland, PhD What the ‘UNITE’ Technology Platform Could Mean for the Future of Immunotherapy September 25, 2018   Teri Heiland, Ph.D. is the Senior Vice President of Research and Development, and Co-founder, at Immunomic Therapeutics, Inc., a clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. [….]